Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 5:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 302 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Multimodal Uterotonics at the Time of Cesarean Section in Laboring Patients

NCT03904446
Conditions
Uterine Atony With Hemorrhage
Interventions
Methylergonovine, Normal Saline (placebo)
Drug
Lead sponsor
Cynthia Wong
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Iowa City, Iowa
Recruiting No phase listed Observational Accepts healthy volunteers

NIRS Monitoring in Premature Infants

NCT02601339
Conditions
Hemorrhage, Premature Infants, Newborn, Hydrocephalus
Interventions
ETV/CPC
Procedure
Lead sponsor
Boston Children's Hospital
Other
Eligibility
0 Months to 12 Months
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts
Completed Phase 4 Interventional Results available

Ulipristal for Endometriosis-related Pelvic Pain

NCT02213081
Conditions
Endometriosis
Interventions
Ulipristal
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Uterine Fibroids, Endometriosis
Interventions
Relugolix Combination Tablet
Drug
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
120
States / cities
Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 98 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Validating a New Method to Assess Estimated Blood Loss in the Obstetric Population

NCT03404375
Conditions
Pregnancy Complications
Interventions
Gauss Triton system
Device
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
242 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Galveston, Texas
Conditions
Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome
Interventions
Sparsentan
Drug
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Los Angeles, California • Wilmington, Delaware • Miami, Florida + 17 more
Conditions
Leiomyoma, Uterine Fibroids, Uterine Neoplasms, Menorrhagia, Leiomyomatosis
Interventions
Uterine Fibroid Embolization (UFE), Contour SE™ Microspheres, Embosphere® Microspheres
Procedure · Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed No phase listed Observational Accepts healthy volunteers

Does Skyla Insertion Timing Impact Bleeding?

NCT03074903
Conditions
Vaginal Bleeding
Interventions
Intrauterine system
Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Morristown, New Jersey • Newark, New Jersey
Conditions
Leiomyoma, Uterine Hemorrhage
Interventions
Ulipristal acetate (UPA), Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
28
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 23 more
Conditions
Infant, Very Low Birth Weight, Infant, Premature, Ductus Arteriosus, Patent
Interventions
Indomethacin, Placebo
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
2 Hours to 6 Hours
Enrollment
1,202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2001
U.S. locations
9
States / cities
Birmingham, Alabama • Palo Alto, California • Miami, Florida + 6 more
Conditions
Pregnancy Hemorrhage, Postpartum Hemorrhage
Interventions
Survey
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
Not listed
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Recruiting No phase listed Observational Accepts healthy volunteers

Postpartum Ultrasound Evaluation to Assess Risk of Hemorrhage

NCT06898034
Conditions
Pregnancy Related, Post Partum Hemorrhage
Interventions
Ultrasound
Other
Lead sponsor
Endeavor Health
Other
Eligibility
17 Years and older · Female only
Enrollment
1,725 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Evanston, Illinois
Conditions
Uterine Fibroids, Heavy Menstrual Bleeding
Interventions
Elagolix, Placebo for Estradiol/Norethindrone Acetate, Estradiol/Norethindrone Acetate, Placebo for Elagolix
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
92
States / cities
Birmingham, Alabama • Mobile, Alabama • Costa Mesa, California + 79 more
Conditions
Acute Kidney Injury, Ischemia Reperfusion Injury
Interventions
Valproic Acid Solution, Isotonic saline solution
Drug
Lead sponsor
Westat
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Seattle, Washington
Completed No phase listed Observational Accepts healthy volunteers

Abdominal Ultrasound Assessment in the Post-cesarean Patient

NCT02159105
Conditions
Postpartum Hemorrhage, Postsurgical Bleeding, Abdominal Ultrasound, FAST Scan, Non-invasive Hemoglobin Measurement
Interventions
FAST scan and non-invasive hemoglobin measurement
Device
Lead sponsor
Northwestern University
Other
Eligibility
12 Years to 60 Years · Female only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Copper IUD Treatment Observation Study

NCT02519231
Conditions
Menorrhagia
Interventions
Naproxen, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
5
States / cities
Chicago, Illinois • Seattle, Washington
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Prevention of Postpartum Hemorrhage With TXA

NCT03326596
Conditions
Postpartum Hemorrhage
Interventions
Tranexamic Acid 1000 mg/10ml normal saline infusion
Drug
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years to 54 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Diego, California
Conditions
Menorrhagia, Metrorrhagia, Medicated Intrauterine Devices
Interventions
Tamoxifen, Placebo (for Tamoxifen)
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Completed Not applicable Interventional Accepts healthy volunteers

Surgical Success After Laparoscopic vs Abdominal Hysterectomy

NCT01793584
Conditions
Metrorrhagia, Menorrhagia, Leiomyoma, Adenomyosis, Pelvic Pain, Endometriosis, Pelvic Inflammatory Disease
Interventions
Laparoscopic hysterectomy, Abdominal hysterectomy
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Hematuria, Bladder Cancer
Interventions
Valproic Acid
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
21 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Syracuse, New York
Conditions
Von Willebrand Diseases
Interventions
Use of a postpartum diary and additional blood draws., VWF replacement therapy with Wilate, Tranexamic acid
Other · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
11
States / cities
Aurora, Colorado • New Haven, Connecticut • Miami, Florida + 8 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Oral Contraceptives and Subantimicrobial Doxycycline: Effect on Endometrial Matrix Metalloproteinases

NCT01469585
Conditions
Breakthrough Bleeding
Interventions
Doxycycline
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Honolulu, Hawaii
Conditions
Hemorrhage, Gastrointestinal, Myocardial Infarction, Stroke, Kidney Diseases
Interventions
Not listed
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
144,337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Raritan, New Jersey
Completed Not applicable Interventional Accepts healthy volunteers

Optimal Order of Concurrent Office Hysteroscopy and Endometrial Biopsy

NCT02472184
Conditions
Uterine Fibroids, Vaginal Bleeding
Interventions
Office hysteroscopy, Endometrial biopsy
Procedure
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Tampa, Florida